Clinical Trials | October 13, 2022
Dupixent Phase 3 data showed significant histological remission of eosinophilic esophagitis
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
This recognition marks the third time in five years that Merck has been included on Fortune’s Change the World list.
Study achieves primary endpoint of radiographic progression-free survival
Sitagliptin is an active ingredient in JANUVIA, JANUMET and JANUMET XR
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
The policy aspires to reduce cost of logistics in India to be comparable to global benchmarks by 2030
If implemented across the world, it has the capability to save over 100,000 lives annually
Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
Subscribe To Our Newsletter & Stay Updated
